Analyzing Establishment Labs (ESTA) and Its Rivals
Establishment Labs (NASDAQ: ESTA) is one of 28 publicly-traded companies in the “Surgical appliances & supplies” industry, but how does it weigh in compared to its competitors? We will compare Establishment Labs to similar businesses based on the strength of its profitability, analyst recommendations, valuation, risk, institutional ownership, dividends and earnings.
This table compares Establishment Labs and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Establishment Labs Competitors||-132.11%||-34.94%||-20.85%|
23.1% of Establishment Labs shares are owned by institutional investors. Comparatively, 59.6% of shares of all “Surgical appliances & supplies” companies are owned by institutional investors. 9.3% of shares of all “Surgical appliances & supplies” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a breakdown of current recommendations for Establishment Labs and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Establishment Labs Competitors||227||914||1572||81||2.54|
Establishment Labs presently has a consensus target price of $36.67, suggesting a potential upside of 66.59%. As a group, “Surgical appliances & supplies” companies have a potential upside of 9.89%. Given Establishment Labs’ stronger consensus rating and higher probable upside, equities analysts plainly believe Establishment Labs is more favorable than its competitors.
Valuation and Earnings
This table compares Establishment Labs and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Establishment Labs||$61.21 million||-$21.10 million||-19.65|
|Establishment Labs Competitors||$1.38 billion||$141.70 million||18.89|
Establishment Labs’ competitors have higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Establishment Labs competitors beat Establishment Labs on 8 of the 12 factors compared.
Establishment Labs Company Profile
Establishment Labs Holdings Inc., a medical technology company, designs, develops, manufactures, and markets medical devices for aesthetic plastic surgery, reconstructive plastic surgery, and aesthetic dermatology. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products that is used to remove blood, lipids, and other components from adipose tissue. The company sells its products through exclusive distributors and direct sales force in 60 countries worldwide. Establishment Labs Holdings Inc. was founded in 2004 and is headquartered in Alajuela, Costa Rica.
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.